Multiple Cancer Breakthroughs Are Landing Simultaneously

Three distinct cancer research developments landed in recent months, each attacking the disease from a completely different angle. The media covered each one in isolation, missing the broader pattern.

Drug #1: Stripping Cancer's Invisibility Cloak

Researchers at the Christie NHS Foundation Trust in Manchester developed an experimental drug called GRWD5769. Its job: rip off the disguise cancer cells wear to hide from the immune system.

Immunotherapy works by weaponizing your own immune system against cancer. But tumor cells have learned a trick — they cloak themselves, making immune cells essentially blind to them. Immunotherapy stalls. The cancer spreads.

GRWD5769 removes that cloak.

In a phase 1 trial spanning the UK, France, Spain, and Australia, 83 patients with cervical, bladder, liver, bowel, lung, or head and neck cancers received GRWD5769 alongside the immunotherapy drug cemiplimab, according to The Guardian. Every single participant had already failed previous treatment. Most had no options left.

Tumors shrank in 26 of those 83 patients. Fifteen of them saw reductions of at least 30%.

Disease progression halted for at least six months in 55% of lung cancer patients, 51% of bowel cancer patients, 38% of head and neck cancer patients, 36% of bladder cancer patients, 32% of liver cancer patients, and 18% of cervical cancer patients, according to The Guardian.

Principal investigator Prof. Fiona Thistlethwaite, a consultant medical oncologist and medical director of the Christie clinical research facility, presented the findings at the American Society of Clinical Oncology's annual conference in Chicago — the world's largest cancer conference.

The results across six cancer types in early-stage data are notable.

Drug #2: Shutting Off Cancer's 'Go' Signal Without Breaking Everything Else

Separately, scientists at the Francis Crick Institute and Vividion Therapeutics published a study in the journal Science on October 9, 2025 targeting something called the RAS gene — a mutation present in roughly one in five cancers.

When RAS mutates, it gets stuck in the 'on' position. It keeps sending growth signals nonstop. Cells multiply. Tumors grow.

The obvious fix — block RAS entirely — has a major problem. RAS and its connected enzyme PI3K also regulate blood sugar through insulin. Block PI3K completely, and you give patients dangerous hyperglycemia. Previous drugs caused harmful side effects for exactly this reason.

The Crick/Vividion team found small molecules that permanently attach to PI3K specifically at the spot where RAS connects to it — blocking the cancer signal while leaving insulin regulation intact, according to ScienceDaily.

In mice with RAS-mutated lung tumors, the treatment stopped tumor growth. Blood sugar remained normal. They then combined it with existing cancer drugs and tested it on breast tumor models. It worked there too.

Human trials are now starting. RAS mutations show up in pancreatic, lung, and colon cancers — among the deadliest and hardest-to-treat.

Drug #3: Pancreatic Cancer — The One That Was a Death Sentence

Pancreatic cancer has a five-year survival rate of 13%, according to the American Cancer Society. About 70,000 Americans are diagnosed every year. Roughly 80% of those diagnoses come at a late stage, when options are almost nonexistent.

NPR profiled Vicky Stinson, 65, a retired landscape architect diagnosed with Stage 3 pancreatic cancer in 2024. A doctor told her she had months — not years — to live.

Two years later, she's still here. The drug keeping her alive: daraxonrasib, which works by targeting and killing cancer cells carrying a specific common mutation.

NPR also noted additional experimental approaches in the pipeline: an individualized mRNA vaccine and a device delivering alternating electrical fields directly to the abdomen.

None of these are cures. For a disease that was functionally a death sentence at late-stage diagnosis, the emerging options represent a significant shift.

What the Media Is Getting Wrong

The Daily Wire's coverage on GRWD5769 was thin — mostly a headline with no real substance behind it. NPR gave the pancreatic cancer story genuine depth but treated it as a standalone human-interest piece rather than part of a broader wave of oncology advances. The Guardian did the best reporting on GRWD5769 with actual numbers and a named researcher.

No coverage mapped all three breakthroughs together or pointed out they're attacking different pieces of the same problem: cancer's ability to hide, grow, and resist treatment.

What This Means for Regular People

These are early-stage results. None of these drugs are at your oncologist's office yet. Phase 1 trials establish safety — larger trials are needed before any of this reaches standard care.

For someone sitting in a waiting room with a terminal diagnosis and zero options left, a drug that shrank tumors in 26 out of 83 patients previously deemed without hope changes the calculation entirely.

Cancer research is moving faster right now than at any point in history. Three separate mechanisms — immune evasion, genetic growth signals, targeted mutation killing — are all being cracked simultaneously.